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Abstract
It has been long established that post-mastectomy radiotherapy reduces the risk of locoregional
failure. A survival advantage, however, has only recently been demonstrated. We here provide a
review of the literature as regards to the current indications for post-mastectomy radiotherapy.
Current indications for post-mastectomy 
radiation
Primary breast carcinoma may be managed surgically with
either mastectomy or breast conserving surgery. Although
radiotherapy following breast conserving surgery is widely
accepted, the role of post-mastectomy radiotherapy
(PMRT) has been a subject for debate for many years.
PMRT has been known since the 1970's to substantially
reduce the risk of locoregional failure (LRF), however, a
disease specific survival and overall survival advantage has
only more recently been demonstrated [1-5]. The systemic
therapy of breast cancer has also evolved since many of
the studies were conducted, raising the issue of how best
to incorporate PMRT into current clinical practice.
Randomized control studies of PMRT have consistently
reported improved rates of locoregional control by two-
thirds regardless of patient characteristics such as age,
treatment era or disease characteristics [5-7]. Only in the
late 1990's was it noted that PMRT conveyed a survival
advantage in high risk patients treated with adjuvant
chemotherapy or hormonal therapy [1-5]. The Danish
82b study of PMRT in premenopausal women receiving
adjuvant CMF chemotherapy reported a reduction in LRF
(9% v. 32%, p < 0.001) and improved 10 year overall sur-
vival (54% v. 45%, p < 0.001) in patients receiving PMRT
[2] with similar results reported in the British Columbia
study [1]. The Danish 82c study assessing PMRT in post-
menopausal women receiving one year adjuvant
tamoxifen also revealed similar reductions in LRF (8% v.
35%, p < 0.001) and improved 10 year overall survival
(45% v. 36%, p = 0.03) [3].
There are a number of reasons why a survival advantage
may not have initially been apparent. Original studies
were conducted in the era prior to adjuvant systemic ther-
apy. The resulting reduction of distant failure with sys-
temic therapy may allow the survival effect of PMRT to be
more evident. Analysis of cause-specific mortality in the
older PMRT studies revealed that the reduction in breast
cancer deaths was cancelled out by an increase in late car-
diac mortality secondary to radiotherapy [6,7]. With mod-
ern radiotherapy techniques delivery of dose to the chest
wall is more uniform and cardiac dose minimized. Older
studies were also not stratified according to risk and being
of small sample size not powered sufficiently to detect a
small survival advantage.
The absolute benefit gained from PMRT is believed great-
est for those at high risk of LRF. There is consensus that
PMRT should be considered when risk of LRF is greater
than 20%, such as for patients with four or more positive
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axillary lymph nodes, primary tumour size 5 cm or more,
T4 disease and positive/very close margin [8-11]. PMRT is
not indicated in patients with tumours less than 5 cm in
size and negative axillary nodes as there is only small ben-
efit in terms of locoregional control, and insignificant
absolute survival advantage. Several studies have sug-
gested other factors that may contribute to risk of LRF par-
ticularly when present in combination [8-11]. These
include age less than 40 years, histological grade 3
tumours, presence of lymphovascular invasion, less than
6 nodes removed at axillary dissection and significant
nodal extracapsular spread (> 2 mm). The merit of PMRT,
however, in this group of patients is not known.
It remains unclear whether patients with one to three axil-
lary nodes positive benefit significantly from PMRT. A
number of collaborative groups (including the Eastern
Cooperative Oncology Group, the International Breast
Cancer Study Group and the National Surgical Adjuvant
Breast and Bowel Project) have reported patterns of LRF
following mastectomy in a number of their trials and have
reported that this group of patients experience a LRF rate
of 13–19% compared with 30–33% as reported in the key
randomised trials [8-11]. This discrepancy may be
explained by limited axillary dissection underestimating
the true extent of axillary nodal involvement as only a
median of 7 axillary nodes were removed in the Danish
study and 11 nodes in the British Columbia study com-
pared with 15–17 nodes in these other studies (which
were not directly investigating the value of PMRT). A sub-
set analysis of the Danish 82 b and c studies has been per-
formed including only those with 8 or more axillary
nodes removed reporting continued significant and equal
reductions in LRF and overall survival at 15 years with
PMRT in both the one to three and greater than four
involved node groups[4]. LRF, however, remained high in
the subgroup analysed and the caveat remains that the
extent of adjuvant systemic therapy received in the Danish
studies was less than current clinical practice which may
affect the perceived benefit of PMRT in this group. To
resolve whether patients with one to three positive axillary
nodes should undergo PMRT a phase III randomised con-
trol trial – the Selective Use of Post-operative Radiother-
apy after Mastectomy (SUPREMO) trial – is currently
being conducted in Europe randomising patients with
tumours less than 5 cm in size and 0–3 positive axillary
nodes.
The commonest site of LRF following mastectomy and
axillary nodal dissection is the chest wall (50–75%) fol-
lowed by the supraclavicular fossa and infraclavicular
region (20–40%) [8,9]. The rate of axillary recurrence fol-
lowing a level I/II axillary dissection is < 5% at 10 years
[12,13] and as such the axilla is not routinely irradiated as
part of PMRT. Furthermore, irradiating the entire axilla
following axillary dissection would significantly increase
the rate of chronic arm morbidity and lymphoedema
[14,15].
Irradiation of the internal mammary nodal region
remains controversial. Clinical evidence of recurrence at
this site appears uncommon [8-11] despite older surgical
reports suggesting high rates of involvement [16,17]. The
Danish and British Columbia studies incorporated inter-
nal mammary nodal irradiation [1-3] but its contribution
to survival is unclear. There remains a particular concern
regarding radiation dose to the heart from treatment of
the internal mammary chain and thereby increased risk of
late cardiac toxicity. Results from the European Organisa-
tion for Research and Treatment of Cancer (EORTC)
22922 and the National Cancer Institute of Canada Clin-
ical Trials Group (NCIC CTG) MA20 randomised trials
may provide further clarification.
Systemic therapy of early breast cancer has evolved con-
siderably since many of the PMRT studies were conducted.
Women are more likely to receive more cardiotoxic adju-
vant systemic therapy. There is a significant survival
advantage to anthracyline based regimens compared to
CMF [18], and as a result anthracyclines are now routinely
incorporated into most adjuvant chemotherapy sched-
ules. High risk patients may also receive taxanes following
evidence of a further survival advantage when added to
anthracyclines [19,20]. Furthermore, recent studies have
demonstrated a survival benefit from the addition of tras-
tuzumab in patients with HER2-positive tumours [21,22].
The potential cardiotoxicity of trastuzumab is now well-
established. Whether PMRT offers a further advantage in
patients receiving optimal systemic adjuvant therapy is
unclear. However, the MD Anderson Cancer Center and
the NSABP series assessing locoregional recurrence in
patients receiving anthracycline based chemotherapy sug-
gest that locoregional failure remains an important con-
cern [9,11]. The current recommended duration of
adjuvant hormonal therapy is 5 years, compared to one as
in the Danish 82c study, which may also have an impact
on LRF. Furthermore, in postmenopausal women, the
aromatase inhibitors (AIs) are increasingly being used
instead of tamoxifen. AIs have been shown to reduce both
local and distal relapse compared to tamoxifen [23-26].
Conclusion
PMRT reduces the risk of LRF and increases overall sur-
vival in high risk patients. Current indications for PMRT
include axillary nodal involvement of 4 or more nodes,
disease 5 cm or more in size, T4 disease and positive sur-
gical margins. The potential benefits of PMRT in patients
with < 4 positive axillary nodes remain controversial and
recruitment to ongoing clinical trials should be encour-
aged.International Seminars in Surgical Oncology 2009, 6:5 http://www.issoonline.com/content/6/1/5
Page 3 of 4
(page number not for citation purposes)
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MVV performed literature search, reviewed literature and
drafted manuscript. YSC assisted literature search and in
drafting of manuscript. AM proposed the review, revised
manuscript critically for intellectual content. All authors
read and approved the final manuscript
References
1. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, Wil-
son KS, Knowling MA, Coppin CM, Paradis M, Coldman AJ, Olivotto
IA: Adjuvant radiotherapy and chemotherapy in node-posi-
tive premenopausal women with breast cancer.  N Engl J Med
1997, 337(14):956-62.
2. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F,
Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K: Post-
operative radiotherapy in high-risk premenopausal women
with breast cancer who receive adjuvant chemotherapy.
Danish Breast Cancer Cooperative Group 82b Trial.  N Engl J
Med 1997, 337(14):949-55.
3. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Anders-
son M, Kamby C, Kjaer M, Gadeberg CC, Rasmussen BB, Blichert-
Toft M, Mouridsen HT: Postoperative radiotherapy in high-risk
postmenopausal breast-cancer patients given adjuvant
tamoxifen: Danish Breast Cancer Cooperative Group DBCG
82c randomised trial.  Lancet 1999, 353(9165):1641-8.
4. Overgaard M, Nielsen HM, Overgaard J: Is the benefit of postmas-
tectomy irradiation limited to patients with four or more
positive nodes, as recommended in international consensus
reports? A subgroup analysis of the DBCG 82 b&c rand-
omized trials.  Radiother Oncol 2007, 82(3):247-53.
5. Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML: Does locore-
gional radiation therapy improve survival in breast cancer? A
meta-analysis.  J Clin Oncol 2000, 18(6):1220-9.
6. Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C,
Peto R, Baum M, Fisher B, Host H, et al.: Cause-specific mortality
in long-term survivors of breast cancer who participated in
trials of radiotherapy.  J Clin Oncol 1994, 12(3):447-53.
7. Favourable and unfavourable effects on long-term survival of
radiotherapy for early breast cancer: an overview of the ran-
domised trials. Early Breast Cancer Trialists' Collaborative
Group.  Lancet 2000, 355(9217):1757-70.
8. Recht A, Gray R, Davidson NE, Fowble BL, Solin LJ, Cummings FJ,
Falkson G, Falkson HC, Taylor SG 4th, Tormey DC: Locoregional
failure 10 years after mastectomy and adjuvant chemother-
apy with or without tamoxifen without irradiation: experi-
ence of the Eastern Cooperative Oncology Group.  J Clin Oncol
1999, 17(6):1689-700.
9. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A,
Hortobagyi G, Buzdar AU, Theriault R, Singletary SE, McNeese MD:
Locoregional recurrence patterns after mastectomy and
doxorubicin-based chemotherapy: implications for postop-
erative irradiation.  J Clin Oncol 2000, 18(15):2817-27.
10. Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gert-
sch M, Holmberg SB, Lindtner J, Thürlimann B, Fey M, Werner ID,
Forbes JF, Price K, Coates AS, Collins J, International Breast Cancer
Study Group Trials I through VII: Risk factors for locoregional
recurrence among breast cancer patients: results from
International Breast Cancer Study Group Trials I through
VII.  J Clin Oncol 2003, 21(7):1205-13.
11. Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M,
Wolmark N: Patterns of locoregional failure in patients with
operable breast cancer treated by mastectomy and adjuvant
chemotherapy with or without tamoxifen and without radi-
otherapy: results from five National Surgical Adjuvant
Breast and Bowel Project randomized clinical trials.  J Clin
Oncol 2004, 22(21):4247-54.
12. Strom EA, Woodward WA, Katz A, Buchholz TA, Perkins GH, Jhin-
gran A, Theriault R, Singletary E, Sahin A, McNeese MD: Clinical
investigation: regional nodal failure patterns in breast cancer
patients treated with mastectomy without radiotherapy.  Int
J Radiat Oncol Biol Phys 2005, 63(5):1508-13.
13. Recht A, Pierce SM, Abner A, Vicini F, Osteen RT, Love SM, Silver B,
Harris JR: Regional nodal failure after conservative surgery
and radiotherapy for early-stage breast carcinoma.  J Clin
Oncol 1991, 9(6):988-96.
14. Suneson BL, Lindholm C, Hamrin E: Clinical incidence of lym-
phoedema in breast cancer patients in Jonkoping County,
Sweden.  Eur J Cancer Care (Engl) 1996, 5(1):7-12.
15. Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA:
Chronic arm morbidity after curative breast cancer treat-
ment: prevalence and impact on quality of life.  J Clin Oncol
2002, 20(20):4242-8.
16. Urban JA, Marjani MA: Significance of internal mammary lymph
node metastases in breast cancer.  Am J Roentgenol Radium Ther
Nucl Med 1971, 111(1):130-6.
17. Morrow M, Foster RS Jr: Staging of breast cancer: a new ration-
ale for internal mammary node biopsy.  Arch Surg 1981,
116(6):748-51.
18. Early Breast Cancer Trialists' Collaborative Group (EBCTCG):
Effects of chemotherapy and hormonal therapy for early
breast cancer on recurrence and 15-year survival: an over-
view of the randomised trials.  Lancet 2005,
365(9472):1687-717.
19. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch
A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A,
Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M,
Valagussa P, Bonadonna G, European Cooperative Trial in Operable
Breast Cancer Study Group: Improved outcomes from adding
sequential Paclitaxel but not from escalating Doxorubicin
dose in an adjuvant chemotherapy regimen for patients with
node-positive primary breast cancer.  J Clin Oncol 2003,
21(6):976-83.
20. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver
C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A,
Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter
T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-
Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M,
Riva A, Vogel C, Breast Cancer International Research Group 001
Investigators: Adjuvant docetaxel for node-positive breast can-
cer.  N Engl J Med 2005, 352(22):2302-13.
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch
M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D,
Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M,
Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter
TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden
E, Dolci MS, Gelber RD, Herceptin Adjuvant (HERA) Trial Study
Team: Trastuzumab after adjuvant chemotherapy in HER2-
positive breast cancer.  N Engl J Med 2005, 353(16):1659-72.
22. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE,
Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM,
Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G,
Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein
PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemo-
therapy for operable HER2-positive breast cancer.  N Engl J
Med 2005, 353(16):1673-84.
23. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sah-
moud T, The ATAC (Arimidex, Tamoxifen Alone or in Combination)
Trialists' Group: Anastrozole alone or in combination with
tamoxifen versus tamoxifen alone for adjuvant treatment of
postmenopausal women with early-stage breast cancer:
results of the ATAC (Arimidex, Tamoxifen Alone or in
Combination) trial efficacy and safety update analyses.  Can-
cer 2003, 98(9):1802-10.
24. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T,
Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dod-
well D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning
PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M,
Massimini G, Bliss JM, Velde C van de, Intergroup Exemestane Study:
A randomized trial of exemestane after two to three years
of tamoxifen therapy in postmenopausal women with pri-
mary breast cancer.  N Engl J Med 2004, 350(11):1081-92.
25. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castigli-
one M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE,
Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL: A
randomized trial of letrozole in postmenopausal womenPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
International Seminars in Surgical Oncology 2009, 6:5 http://www.issoonline.com/content/6/1/5
Page 4 of 4
(page number not for citation purposes)
after five years of tamoxifen therapy for early-stage breast
cancer.  N Engl J Med 2003, 349(19):1793-802.
26. Breast International Group (BIG) 1–98 Collaborative Group, Thürli-
mann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF,
Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I,
Wardley A, Price KN, Goldhirsch A: A comparison of letrozole
and tamoxifen in postmenopausal women with early breast
cancer.  N Engl J Med 2005, 353(26):2747-57.